CS
ZNTL icon

Candriam SCA’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Candriam SCA’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-127,973
Closed -$2.58M – 939
2022
Q4 		$2.58M Hold
127,973
– – 0.02% 529
2022
Q3 		$2.77M Hold
127,973
– – 0.02% 512
2022
Q2 		$3.6M Hold
127,973
– – 0.03% 379
2022
Q1 		$5.9M Sell
127,973
-8,253
-6% -$445K 0.04% 321
2021
Q4 		$11.5M Sell
136,226
-72,300
-35% -$5.59M 0.07% 245
2021
Q3 		$13.9M Hold
208,526
– – 0.09% 225
2021
Q2 		$11.1M Buy
208,526
+208,515
+1,895,591% +$11.2M 0.08% 273
2021
Q1 		$0 Buy
+11
New +$474 ﹤0.01% 821

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Candriam SCA's ZNTL Position: Q1 2023 in Review

Candriam SCA sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2023, closing a stake of 127,973 shares — an estimated $2.58M sold.

Candriam SCA first reported a position in ZNTL in Q1 2021 and held it in 8 quarters. The position peaked at $13.9M in Q3 2021. 110 funds tracked by Wall St. Rank hold ZNTL as of Q1 2023.

  • Candriam SCA reported no remaining Zentalis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 127,973 Zentalis Pharmaceuticals shares in Q1 2023, an estimated $2.58M.
  • Candriam SCA first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Candriam SCA's Zentalis Pharmaceuticals position peaked at $13.9M in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.